Search clinical trials for: CORT125134

Total 19 results

Corcept Therapeutics

Completed

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Hepatic Impairment

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

Healthy

United States
Corcept Therapeutics

Completed

A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body

Healthy

United Kingdom
Corcept Therapeutics

Completed

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

Healthy

United States
Corcept Therapeutics

Completed

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Cushing's Syndrome

Netherlands, United States, Hungary, Italy, United Kingdom
Corcept Therapeutics

Enrolling by invitation

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Cushing Syndrome

United States, Austria, Bulgaria, Germany, Israel, Italy, Netherlands, Romania, Spain, Poland, Canada
Corcept Therapeutics

Active, not recruiting

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE)

Cushing Syndrome

United States, Austria, Bulgaria, Canada, Germany, Israel, Italy, Netherlands, Poland, Romania, Spain
Corcept Therapeutics

Completed

Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants

Healthy

United Kingdom
Corcept Therapeutics

Completed

Relacorilant Food Effect Study in Healthy Subjects

Healthy | Food-drug Interaction

United States
Corcept Therapeutics

Completed

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Adrenocortical Carcinoma

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

Healthy

United States
Corcept Therapeutics

Completed

A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants

Healthy

United States
Corcept Therapeutics

Completed

CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Healthy

United Kingdom
Corcept Therapeutics

Completed

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Solid Tumors

United States
Corcept Therapeutics

Terminated

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT)

Metastatic Pancreatic Ductal Adenocarcinoma

United States
Corcept Therapeutics

Completed

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

Healthy

United States
Corcept Therapeutics

Active, not recruiting

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States, Belgium, Canada, Italy, Spain
Corcept Therapeutics

Completed

Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

Healthy

United States
Corcept Therapeutics

Completed

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

Healthy

United States

3

Subscribe